Lunit Meets MDR CE Requirements for 3D Breast Tomosynthesis AI Solution
- Written by PR Newswire
- Lunit set to launch Lunit INSIGHT DBT in the European market
- Lunit seeks FDA clearance, paving the way into the US market
SEOUL, South Korea, March 20, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer solutions, today announced that its AI solution for 3D Breast Tomosynthesis (DBT) analysis, Lunit INSIGHT...
Read more: Lunit Meets MDR CE Requirements for 3D Breast Tomosynthesis AI Solution














